v3.26.1
Acquisitions of Assets - Additional Information (Details)
shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2025
USD ($)
May 31, 2024
USD ($)
Nov. 30, 2023
USD ($)
Sep. 30, 2021
USD ($)
Agreements
shares
Dec. 31, 2023
USD ($)
Jun. 30, 2026
USD ($)
Milestones
Dec. 31, 2020
USD ($)
Amgen Inc.              
Business Combination [Line Items]              
Number of license agreements | Agreements       2      
Vanderbilt IPR&D Assets              
Business Combination [Line Items]              
Contingent consideration deemed due or payable           $ 0  
BlackThorn Merger Agreement              
Business Combination [Line Items]              
Contingent consideration, milestone payment settled in cash             $ 10,000,000
BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc.              
Business Combination [Line Items]              
Contingent consideration deemed due or payable           $ 0  
BlackThorn Merger Agreement | navacaprant | Maximum | Development and Regulatory Approval Milestones              
Business Combination [Line Items]              
Contingent consideration             365,000,000
BlackThorn Merger Agreement | navacaprant | Maximum | Sales-based Milestones              
Business Combination [Line Items]              
Contingent consideration             450,000,000
BlackThorn Merger Agreement | NMRA-511 | Maximum | Development and Regulatory Approval Milestones              
Business Combination [Line Items]              
Contingent consideration             100,000,000
BlackThorn Merger Agreement | NMRA-511 | Maximum | Sales-based Milestones              
Business Combination [Line Items]              
Contingent consideration             $ 100,000,000
Amgen Inc. Licenses | Amgen Inc.              
Business Combination [Line Items]              
Number of milestone achieved | Milestones           0  
Contingent consideration deemed due or payable           $ 0  
Amgen Inc. Licenses | Amgen Inc. | Series A-2              
Business Combination [Line Items]              
Upfront consideration transferred shares | shares       20.0      
Acquisition date fair value of shares transferred       $ 157,000,000      
Amgen Inc. Licenses | Amgen Inc. | Maximum | Case One              
Business Combination [Line Items]              
Contingent consideration payable in cash       360,000,000      
Amgen Inc. Licenses | Amgen Inc. | Maximum | Commercial Milestone Payment | Case Two              
Business Combination [Line Items]              
Contingent consideration payable in cash       $ 360,000,000      
Vanderbilt License              
Business Combination [Line Items]              
Contingent consideration, milestone payment settled in cash $ 5,000,000   $ 2,000,000        
Number of milestone achieved | Milestones           0  
Acquired in-process research and development         $ 800,000    
Vanderbilt License | Maximum | Achievement of Specified Development Events              
Business Combination [Line Items]              
Contingent consideration payable in cash   $ 42,000,000          
Vanderbilt License | Maximum | Achievement of Specified Commercialization Events              
Business Combination [Line Items]              
Contingent consideration payable in cash   380,000,000          
Vanderbilt License | Vanderbilt IPR&D Assets              
Business Combination [Line Items]              
Upfront cash payment   $ 13,000,000